Cancer chemoprevention by targeting proteasomal degradation: commentary re KA Dragnev et al, Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy. Clin Cancer Res, 2004;10:2570-7.
Yang
Chung S
CS
Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey, USA.
Chin
Khew-Voon
KV
Lambert
Joshua D
JD
D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D019938:Cyclin D1 / Q000378:metabolism; D019927:Cyclin E / Q000378:metabolism; D006801:Humans; D008954:Models, Biological; D009369:Neoplasms / Q000517:prevention & control*; D010766:Phosphorylation; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism*; D018168:Receptors, Retinoic Acid / Q000378:metabolism; D016160:Retinoblastoma Protein / Q000378:metabolism; D025801:Ubiquitin / Q000378:metabolism
D016588:Anticarcinogenic Agents; D019927:Cyclin E; D018168:Receptors, Retinoic Acid; D016160:Retinoblastoma Protein; D025801:Ubiquitin; C082925:retinoic acid receptor beta; D019938:Cyclin D1; D046988:Proteasome Endopeptidase Complex